Considering Equity and Consumer Impacts of GLP-1 Drugs – A UBS Economist Weighs In
Since the introduction of GLP-1 drugs on the market, their use has split into two categories: for obesity and “recreationally,” according to the Chief Economist with UBS (formerly known as...